rtmark
LearnBonds.com

Vir Biotechnology stock soars after GlaxoSmithKline snaps up $250m stake for virus drug

British drugmaker GlaxoSmithKline (NYSE: GSK) said it will buy a $250m stale in Vir Biotechnology to advance the US firm’s potential treatments for coronavirus, a disease that killed almost 75,000 people and infected more than 1.3 million people across the globe.

GSK said cash will be used to accelerate Vir’s very “promising antibody candidates” , VIR-7831, and VIR-7832 in Phase II clinical trials “within the next three to five months”.

GlaxoSmithKline disclosed that they will bear 72.5% of the antibody program cost, 27.5% of the vaccine development program, and both companies will share half of the development costs related to the functional genomics program.

“Vir’s unique antibody platform has precedented success in identifying and developing antibodies as treatments for multiple pathogens, and it is highly complementary with our R&D approach to focus on the science of immunology,” Hal Barron, GSK’s chief scientific officer and president of R&D, said in a statement on Monday.

Vir Biotechnology stock soars...

San Francisco-based Vir’s stock price jumped 26% after the news as investors appreciated the collaboration between both companies. GlaxoSmithKline stock, on the other hand, liftedonly 2% because of its big size when compared to Vir Biotechnology.

GlaxoSmithKline stock price currently trades around $37, down from a 52-weeks high of $48 a share. It had generated year over year revenue growth of 8.5% in the latest quarter while the full-year sales increased 10% year over year to £33.8bn. The company has generated net cash flow from operating activities of £8bn and the free cash flow stood around £5.1bn.

“In 2020, our first priority remains Innovation, to progress our pipeline and support new product launches. Recent data readouts underpin our decision to further increase investment in R&D and these new products. At the same time, we are again focused on operational execution,” Emma Walmsley, GSK chief executive officer said.

Trusted & Regulated Stock & CFD Brokers

Rating

What we like

  • 0% Fees on Stocks
  • 5000+ Stocks, ETFs and other Markets
  • Accepts Paypal Deposits

Min Deposit

$200

Charge per Trade

Zero Commission

Rating

64 traders signed up today

Visit Now

75% of investors lose money when trading CFDs.

Available Assets

  • Total Number of Stocks & Shares5000+
  • US Stocks
  • German Stocks
  • UK Stocks
  • European
  • ETF Stocks
  • IPO
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 Zero Commission
  • NASDAQ Zero Commission
  • DAX Zero Commission
  • Facebook Zero Commission
  • Alphabet Zero Commission
  • Tesla Zero Commission
  • Apple Zero Commission
  • Microsoft Zero Commission

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
  • Paypall
  • Skrill
  • Neteller

Rating

What we like

  • Sign up today and get $5 free
  • Fractals Available
  • Paypal Available

Min Deposit

$0

Charge per Trade

$1 to $9 PCM

Rating

Visit Now

Investing in financial markets carries risk, you have the potential to lose your total investment.

Available Assets

  • Total Number of Shares999
  • US Stocks
  • German Stocks
  • UK Stocks
  • European Stocks
  • EFTs
  • IPOs
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 $1 - $9 per month
  • NASDAQ $1 - $9 per month
  • DAX $1 - $9 per month
  • Facebook $1 - $9 per month
  • Alphabet $1 - $9 per month
  • Telsa $1 - $9 per month
  • Apple $1 - $9 per month
  • Microsoft $1 - $9 per month

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
Users should remember that all trading carries risks and users should only invest in regulated firms. Views expressed are those of the writers only. Past performance is no guarantee of future results. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.
Avatar

Based in Saudi Arabia, Siraj has a strong understanding of and passion for accounting and finance. He has worked for international clients for many years on several projects related to the stock market, equity research and other business, accounting and finance related projects. Siraj is a published financial analyst on the world's leading websites including SeekingAlpha, TheStreet, MSN, and others.